Recruiting Psoriasis Studies in Rochester
About Psoriasis Clinical Trials in Rochester
Psoriasis is a chronic autoimmune skin condition affecting over 8 million Americans, causing cells to build up rapidly on the surface and forming red, scaly patches that can be itchy and painful. Plaque psoriasis accounts for about 80-90% of cases. While current treatments include topical therapies, phototherapy, and biologics like TNF inhibitors (adalimumab, etanercept) and IL-17/IL-23 inhibitors (secukinumab, guselkumab), clinical trials are testing next-generation oral treatments, TYK2 inhibitors, and combination approaches that may offer longer remission periods with fewer side effects. Patients with moderate-to-severe psoriasis who have not responded adequately to existing therapies are often sought for clinical trial enrollment.
There are currently 2 psoriasis clinical trials recruiting participants in Rochester, MI. These studies are seeking a combined 476 participants. Research is being sponsored by Vanda Pharmaceuticals, NYU Langone Health. Clinical trial participation is free and participants receive study-related medical care at no cost.
Psoriasis Clinical Trials in Rochester — FAQ
Are there psoriasis clinical trials in Rochester?
Yes, there are 2 psoriasis clinical trials currently recruiting in Rochester, MI. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Rochester?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Rochester research site will contact you about next steps.
Are clinical trials in Rochester free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Rochester studies also compensate for your time and travel.
What psoriasis treatments are being tested?
The 2 active trials in Rochester are testing new therapies including novel drugs, biologics, and treatment approaches for psoriasis.
Data updated July 13, 2026 from ClinicalTrials.gov